Abstract: An implantable cranial medical device includes a first fluid flow path, a second fluid flow path, and upper flange portion, and a lower portion. The upper flange portion is configured to rest on a skull of a subject about a burr hole. The lower portion is configured to be placed within the burr hole. The first fluid flow path may extend from a first opening in the upper flange portion to a first opening in the lower portion. The second fluid flow path may extend from a second opening in the upper flange portion to a second opening in the lower portion.

Abstract: An implantable cranial medical device includes a first fluid flow path, a second fluid flow path, and upper flange portion, and a lower portion. The upper flange portion is configured to rest on a skull of a subject about a burr hole. The lower portion is configured to be placed within the burr hole. The first fluid flow path may extend from a first opening in the upper flange portion to a first opening in the lower portion. The second fluid flow path may extend from a second opening in the upper flange portion to a second opening in the lower portion.

Abstract: According to the subject invention, there is disclosed, a dosage and packaging configuration which includes the use of color-coded pre-filled syringes and vials to fill and refill infusion systems with existing and new dosage forms of intrathecal baclofen.

Abstract: The present disclosure relates generally to a pharmaceutical solution comprising hydromorphone or a pharmaceutically acceptable salt thereof that is substantially free of buffer and optionally one or more other additives. The pharmaceutically acceptable salt may be hydromorphone hydrochloride. Also disclosed are methods for the manufacture and use of the solution.

Abstract: The present invention relates generally to a sterile, particulate-free, stable intrathecal baclofen solution with less than 0.5% of 4-(4-chlorophenyl)-2-pyrrolidone, a degradation product. These solutions are stable under a variety of storage conditions and for extended periods of time. Also disclosed are methods for preparing such compositions.

Abstract: According to the subject invention, there is disclosed, a dosage and packaging configuration which includes the use of color-coded pre-filled syringes and vials to fill and refill infusion systems with existing and new dosage forms of intrathecal baclofen.

Abstract: The present invention relates generally to a sterile hydromorphone hydrochloride solution that is substantially free of buffer.

Abstract: The present invention relates generally to a sterile hydromorphone hydrochloride solution that is substantially free of buffer.

Abstract: According to the subject invention, there is disclosed, a dosage and packaging configuration which includes the use of color-coded pre-filled syringes and vials to fill and refill infusion systems with existing and new dosage forms of intrathecal baclofen.

Abstract: The present disclosure relates generally to a pharmaceutical solution comprising hydromorphone or a pharmaceutically acceptable salt thereof that is substantially free of buffer and optionally one or more other additives. The pharmaceutically acceptable salt may be hydromorphone hydrochloride. Also disclosed are methods for the manufacture and use of the solution.

Abstract: The present invention relates generally to a sterile hydromorphone hydrochloride solution that is substantially free of buffer.

Abstract: According to the subject invention, there is disclosed, a dosage and packaging configuration which includes the use of color-coded pre-filled syringes and vials to fill and refill infusion systems with existing and new dosage forms of intrathecal baclofen.

Abstract: The invention provides methods and devices to treat obesity by ablating tissue from an exterior surface of a stomach of a patient. For example, the invention may involve ablation of exterior stomach tissue to alter gastric myoelectric activity or muscle function from the exterior surface of the stomach to produce abnormal gastric peristalsis without damaging the mucosal lining of the stomach. The invention may further provide methods and devices to monitor the gastric myoelectric activity before and after the ablation procedure.

Abstract: The invention provides methods and devices to reduce stomach acid secretion in a patient with a hyper acid condition. For example, the invention may involve ablation of the stomach lining to destroy acid-producing cells. Destroying acid-producing cells may reduce the amount of stomach acid produced and, therefore the amount of acid refluxed in the esophagus. The invention may further provide methods and devices to monitor the esophageal acid level before and after the ablation procedure.

Abstract: The invention provides methods and devices for ablation of stomach tissue to treat obesity. For example, the invention may involve ablation of mucosal tissue to inhibit ghrelin production, recognized as a root cause of increased appetite. The invention alternatively may involve ablation of sub-mucosal tissue to alter myoelectric activity and thereby induce gastroparesis. As a further alternative, gastric muscle tissue, vagal nerves within the stomach or the pyloric region may be ablated to alter stomach function and thereby induce gastroparesis.

Abstract: An implantable drug delivery device comprising a microencapsulated drug contained within at least one capsule, a carrier fluid that will dissolve the drug when freed from the capsule, a drug releaser for freeing the microencapsulated drug from the capsule, a reservoir in which the carrier fluid dissolves the drug, and an electromechanical pump to convey the dissolved drug to a catheter, through which the drug is delivered to a target site within a patient.

Abstract: A glide test head assembly glide test head assembly in which the mounting orientation of the piezo element has been modified. The glide test head assembly mounts the piezo element with one of its major surfaces coincident with the surface of the laterally-extending wing on which it is mounted. The mounting orientation of the piezo element allows the piezo element to be mounted fully on the laterally-extending wing of the glide test head assembly, raising the resonant frequency of the piezo element, decreasing the glide test head assembly's sensitivity to excitation caused by air flow disturbances, and increasing the reliability of glide test results.

Abstract: A head suspension assembly for mounting and supporting a head in a disc drive which includes a preloaded gimbal assembly. The preloaded gimbal assembly acts, during certain applied mechanical shock events, to prevent separation of the head and the disc which can lead to damaging contact between the head and the disc. Various design and manufacturing considerations necessary to implementation of the invention are disclosed.

Abstract: A disc mounting system for mounting the discs of a disc drive in a fixed radial relationship to the hub of a spindle motor. The disc mounting system includes a radially-loaded, snap-fit disc mounting ring associated with each disc. The disc mounting rings include disc contact features for interaction with the inner diameters of the discs, and hub contact features for axially positioning the discs and associated disc mounting rings relative to the spindle motor hub. Various embodiments of the disc mounting ring are disclosed.

Abstract: An implantable system for infusing a fluid agent and providing electrical stimulation without requiring an implanted pump or implanted source of electrical energy. An implantable housing is fitted with a percutaneous fill port that communicates with a reservoir to hold a fluid agent, such as a drug. An antenna located inside the housing receives radio frequency power signals from an outside antenna. A pulse generator outside the housing receives power and information from the radio frequency signals to produce stimulation pulses. The pulses and the fluid agent are both transported by a catheter to a site of application in the body. A connector allows the stimulation pulses and fluid agent to be transported from the housing to the catheter while maintaining electrical isolation between the stimulating pulses and the fluid agent.